Alnylam Pharmaceuticals held an RNAi roundtable to discuss Brezosiran (ALN-HTT02), a drug in development for Huntington's disease. Experts including Alnylam's research leaders and Dr. Gill Bates from University College London explained the importance of targeting the HTT1a isoform and Exon1 in the disease. The event included a presentation and a Q&A session to share progress and insights on this potential treatment. Recordings are available on Alnylam's website for further review.
Alnylam Pharmaceuticals (ALNY) trades at USD 227.89 on Pluang as of Oct 27, 2026 10:21 WIB, showing a modest 1.72% gain for the day. This price is closer to its 52-week low of USD 205.48 than its 52-week high of USD 481.59, indicating the stock remains well below its peak levels despite recent positive developments. Investors typically hold ALNY for about 41 days on the platform, reflecting a moderate trading horizon.
